3 Things About Vertex Pharmaceuticals That Smart Investors Know
Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next blockbuster product. Vertex and partner CRISPR Therapeutics hope to launch exa-cel, a gene-editing treatment for blood disorders, as soon as next year.
This is a huge deal for Vertex because it would represent the company's first product outside of its cystic fibrosis (CF) specialty area. A few years ago, investors worried that Vertex would struggle to move beyond CF -- an approval here would prove that Vertex can successfully expand. So, it's no surprise that, in recent times, the market's focus has been on exa-cel. But there are three other things about Vertex that smart investors know. And that's why right now is a great time to get in on this big biotech company.
Vertex today brings in billions of dollars thanks to its portfolio of CF drugs, especially the newest one, Trikafta. Regulators approved Trikafta in 2019, and it was cause for excitement. That's because Trikafta has the potential to treat 90% of CF patients. Last year, the drug generated more than $7.6 billion in revenue.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 55 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 450 € is below the current price of 461.3 € for Vertex Pharmaceuticals Inc., so the potential is actually -2.45%.
